Literature DB >> 19306500

Shock the heat shock network.

Cigdem Atay1, Serkan Ugurlu, Nesrin Ozören.   

Abstract

The targeting of tumors is made possible through establishing protein signatures specific for each cancer type. The recent recognition of the higher expression levels of HSP90 and its accumulation in tumor cell mitochondria has made the HSP90 network a feasible target for neutralization. HSP90 antagonizes the mitochondrial permeability transition,blocking cytochrome c release and apoptosis. In this issue of the JCI, Kang et al. report the synthesis of Gamitrinibs, which target mitochondrially localized HSP90, specifically killing human cancer cell lines, and provide a fresh approach for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19306500      PMCID: PMC2648680          DOI: 10.1172/jci38681

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome.

Authors:  H M Beere; B B Wolf; K Cain; D D Mosser; A Mahboubi; T Kuwana; P Tailor; R I Morimoto; G M Cohen; D R Green
Journal:  Nat Cell Biol       Date:  2000-08       Impact factor: 28.824

Review 2.  Oncogenomics and the development of new cancer therapies.

Authors:  Robert L Strausberg; Andrew J G Simpson; Lloyd J Old; Gregory J Riggins
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

Review 3.  Stressed to death: regulation of apoptotic signaling pathways by the heat shock proteins.

Authors:  H M Beere
Journal:  Sci STKE       Date:  2001-07-31

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  Rational design of shepherdin, a novel anticancer agent.

Authors:  Janet Plescia; Whitney Salz; Fang Xia; Marzia Pennati; Nadia Zaffaroni; Maria Grazia Daidone; Massimiliano Meli; Takehiko Dohi; Paola Fortugno; Yulia Nefedova; Dmitry I Gabrilovich; Giorgio Colombo; Dario C Altieri
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

6.  Expression of apoptosis regulators in cutaneous malignant melanoma.

Authors:  L Tang; V A Tron; J C Reed; K J Mah; M Krajewska; G Li; X Zhou; V C Ho; M J Trotter
Journal:  Clin Cancer Res       Date:  1998-08       Impact factor: 12.531

7.  The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining.

Authors:  Y Tsujimoto; J Gorham; J Cossman; E Jaffe; C M Croce
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

8.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

Authors:  Mark D Pegram; Gottfried E Konecny; Carminda O'Callaghan; Malgorzata Beryt; Richard Pietras; Dennis J Slamon
Journal:  J Natl Cancer Inst       Date:  2004-05-19       Impact factor: 13.506

Review 9.  Targeted cancer therapy.

Authors:  Charles Sawyers
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

10.  The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation.

Authors:  Z Chen-Levy; J Nourse; M L Cleary
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

View more
  1 in total

Review 1.  Targeting malignant mitochondria with therapeutic peptides.

Authors:  Jonathan E Constance; Carol S Lim
Journal:  Ther Deliv       Date:  2012-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.